Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 6, 2016, Pages 1369-1376

  Schmidt, Gilda ^a   Gerlinger, Christoph ^a   Juhasz Böss, Ingolf ^a   Stickeler, Elmar ^b   Rody, Achim ^c   Liedtke, Cornelia ^c   Wimberger, Pauline ^d   Link, Theresa ^d   Müller, Eberhard ^e   Fehm, Tanja ^f   Abel, Manuela ^g   Stein, Stefan ^g   Bohle, Rainer ^a   Endrikat, Jan ^a   Solomayer, Erich Franz ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e Hospital St Wendel   (Germany)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g Klinikum Idar Oberstein   (Germany)

Author keywords

DFS; Her2neu score; OS; TNBC

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HER2 NEU SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; CLINICAL TRIAL; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS;

FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84961800990     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-016-2146-z     Document Type: Article

References (38)

1. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32(27):2959–2966
2. Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS (2015) Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology 4(9):e985930 (eCollection 2015)
3. Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB et al (2010) Prognosis and outcome of small (≤1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 15(10):1043–1049
4. Arriagada R, Le MG, Dunant A, Tubiana M, Contesso G (2006) Twenty-five years of follow-up in patients with operable breast carcinoma: correlation between clinicopathologic factors and the risk of death in each 5-year period. Cancer 106(4):743–750
5. Bahreini F, Soltanian AR, Mehdipour P (2014) A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. Breast Cancer 22(6):615–625. doi:10.1007/s12282-014-0528-0
6. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728
7. Bulut N, Aksoy S, Dizdar O, Dede DS, Arslan C, Dogan E et al (2011) Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. Med Oncol 28(Suppl 1):S75–S79
8. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334
9. Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K (2013) Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 8(2):e55910. doi:10.1371/journal.pone.0055910 (Epub 2013 Feb 6)
10. Dalton LW, Pinder SE, Elston CE, Ellis IO, Page DL, Dupont WD et al (2000) Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol 13(7):730–735
11. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434
12. D’Ippolito E, Iorio MV (2013) MicroRNAs and triple negative breast cancer. Int J Mol Sci 14(11):22202–22220
13. Gasparini P, Fassan M, Gascione L et al (2014) Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One. doi:10.1371/journal.pone.0088525.e88525
14. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657
15. Hamm C, El Masri M, Poliquin G, Poliquin V, Mathews J, Kanjeekal S et al (2011) A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. Curr Oncol 18(4):191–196
16. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L et al (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628–2634
17. Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(Suppl 1):1–11
18. Kaplan HG, Malmgren JA, Atwood M (2009) T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 15(5):454–460
19. Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, Blake-Cerda M, Arce C, Motola-Kuba D et al (2011) Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 117(16):3658–3669
20. Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES (2010) Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. Breast Cancer Res Treat 123(1):177–187
21. Lehmann BD, Pietenpol JA (2015) Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast 24(Suppl 2):S36–S40. doi:10.1016/j.breast.2015.07.009 (Epub 2015 Aug 5)
22. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767
23. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281
24. Lin C, Chien SY, Kuo SJ, Chen LS, Chen ST, Lai HW et al (2012) A 10-year follow-up of triple-negative breast cancer patients in Taiwan. Jpn J Clin Oncol 42(3):161–167
25. Lipton A, Kostler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J et al (2010) Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 116(22):5168–5178
26. Luoh SW, Ramsey B, Hanlon NA, Troxell M, Hu Z, Chin K et al (2013) HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression. Springerplus 2:386
27. Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E (2014) Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer. Oncol Lett 7(1):278–284 (Epub 2013 Nov 14)
28. Mrklić I, Pogorelić Z, Ćapkun V, Tomić S (2013) Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem 115(4):344–348. doi:10.1016/j.acthis.2012.09.006
29. Pogoda K, Niwinska A, Murawska M, Pienkowski T (2013) Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 30(1):388
30. Rakha EA, El Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32
31. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L et al (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13(5):R97
32. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27(8):1323–1333
33. Schmidt G, Meyberg-Solomayer G, Gerlinger C, Juhasz-Böss I, Herr D, Rody A, Liedtke C, Solomayer EF (2014) Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression. Arch Gynecol Obstet 290(6):1221–1229. doi:10.1007/s00404-014-3331-4 (Epub 2014 Jul 11)
34. Sutton LM, Cao D, Sarode V et al (2012) Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol 138(4):511–516. doi:10.1309/AJCP8AVF8FDPTZLH
35. Tang D, Xu S, Zhang Q, Zhao W (2012) The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 29(2):526–533. doi:10.1007/s12032-011-9948-2
36. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43
37. Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y (2013) Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol 139(5):739–746. doi:10.1007/s00432-013-1376-6 (Epub 2013 Jan 26)
38. Zhang L, Fang C, Xu X, Li A, Cai Q, Long X (2015) Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis. Biomed Res Int 2015:357485. doi:10.1155/2015/357485 (Epub 2015 Jan 28)